Donlaporn Sritharadol
Head of Bioanalysis, Clinical Pharmacology
Donlaporn Sritharadol is Head of Bioanalysis of Clinical Pharmacology group focusing on advancing bioanalytical sciences to support clinical research, drug development, and regulatory decision-making. Her work aims to generate reliable, high-quality drug concentration data that can be confidently used throughout the drug development pathway, from early research and clinical studies to regulatory submissions and therapeutic optimization.
A major focus of her research is the development, validation, and implementation of bioanalytical methods for the quantification of small molecules in biological matrices using liquid chromatography–tandem mass spectrometry (LC-MS/MS). She is also interested in expanding bioanalytical capabilities through the application of other analytical methodologies to address emerging scientific and clinical needs. Her research seeks to ensure that analytical methods are scientifically robust, fit for purpose, and capable of generating accurate and reproducible data across diverse study settings.
An important component of Donlaporn’s programme is the integration of quality management systems into bioanalytical research. Her work is conducted within laboratories operating under internationally recognised quality standards, including ISO 15189 and ISO 15190, ensuring the reliability, traceability, and integrity of analytical data. By combining scientific innovation with rigorous quality systems, her research aims to strengthen confidence in bioanalytical results and facilitate their use in clinical research, pharmaceutical development, and regulatory applications.
Through collaboration with clinicians, pharmacologists, laboratory scientists, pharmaceutical developers, and regulatory stakeholders, Donlaporn seeks to bridge analytical science and its application in healthcare and medicine development. Her long-term goal is to strengthen bioanalytical capacity and promote the generation of high-quality evidence that supports clinical research, drug development, therapeutic optimization, and regulatory decision-making. Ultimately, her work aims to contribute to the development of safe, effective, and accessible medicines while advancing scientific knowledge across a broad range of therapeutic areas.